FIELD: medicine.
SUBSTANCE: invention relates to a hypoxia-oriented anti-tumoral product containing, as an active ingredient, 3-bromopyruvate 1-isobutanoyl-2-isopropylisothiourea by the formula (I) in doses of 10 to 20 mg/kg, containing 0.1 to 2% of the active substance in solutions for injections or infusions and 1 to 50 mg of the active substance in solid dosage forms.
(I)
EFFECT: proposed is hypoxia-oriented product for treatment of tumours.
1 cl, 3 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR TARGETED THERAPY OF MALIGNANT GROWTHS | 2018 |
|
RU2699558C2 |
COMPLEX ANTIANGIOGENIC AND HYPOXIA-TARGETED ANTITUMOR AGENT | 2022 |
|
RU2804771C1 |
RADIOPROTECTIVE PHARMACOLOGICAL AGENT | 2020 |
|
RU2733883C2 |
METHOD OF PHARMACOLOGICAL PROTECTION FROM IONIZING RADIATION | 2017 |
|
RU2663465C1 |
IMPROVED METHOD FOR OBTAINING RADIOPROTECTIVE AGENT 1-ISOBUTANOYL-2-ISOPROPYLISOTHIOUREA HYDROBROMIDE | 2023 |
|
RU2806650C1 |
INDOL-3-CARBOXIC ACID DERIVATIVES WITH ANTI-TUMOR ACTIVITY | 2022 |
|
RU2782931C2 |
TUMOUR THERAPY AGENT | 2019 |
|
RU2726801C1 |
METHOD FOR CARRYING OUT PHOTODYNAMIC THERAPY OF SOLID EHRLICH CARCINOMA IN MICE | 2021 |
|
RU2774589C1 |
AGENT FOR CORRECTING CYTOTOXIC EFFECTS OF PARANEOPLASTIC PROCESSES AND CHEMOTHERAPY SHOWING ANTICANCER ACTIVITY | 2011 |
|
RU2447888C1 |
ANTICANCER AGENT | 2012 |
|
RU2503450C1 |
Authors
Dates
2021-07-16—Published
2020-09-15—Filed